Current Headlines

  1. Dorian Therapeutics Accesses Novel Compound Library From Ubiquigent

    Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced recently that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule libraries specifically designed to target deubiquitylase (DUB) enzymes

  2. Cyclica Launches Ligand Design, A Powerful Multi-Targeted Drug Design Technology At Collision Conference Toronto

    Cyclica, a leading biotechnology company that commercialized Ligand Express announced its novel, first-in-class drug design technology, Ligand DesignTM on stage at the Collision Conference in Toronto

  3. Researchers Find New Drug Targets For Deadly Lung Disease

    Researchers at the University of Georgia have discovered two new drug targets to treat Acute Respiratory Distress Syndrome, or ARDS, a life-threatening lung condition that makes breathing difficult or impossible

  4. Synlogic Announces Clinical Collaboration To Evaluate SYNB1891 In Combination With PD-L1 Checkpoint Inhibitor In Patients With Advanced Solid Tumors

    Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, recently announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic medicine, SYNB1891, a dual innate immune activator engineered to express a STING agonist, in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumors

  5. Avadel Pharmaceuticals Announces FDA Acceptance Of New Drug Application For AV001

    Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001

  6. Abeona Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ABO-202 Gene Therapy In CLN1 Disease

    Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA).

  7. Thermo Fisher’s Oral Solid Dose Quick To Clinic™ – Milton Park, UK, And Horsham Sites Combine To Speed Products Into Phase I Clinical Trials

    When developing new pharmaceutical products, it is very important to get to the Phase I clinical trial in a fast, efficient and cost-effective way.

  8. Thermo Fisher’s Florence Site On Track For Commercial Spray Drying Services

    Formulation challenges for enhancing the bioavailability of poorly soluble API’s can be solved by spray drying.

  9. Prokaryotics Announces Exclusive Worldwide Licensing Agreement With MEDINA For New Antibiotic Compounds

    Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Fundación MEDINA, the not-for-profit Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia

  10. Gotham Therapeutics And ZoBio Achieve Significant Milestone In Epitranscriptomic Drug Discovery Collaboration

    Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ZoBio, the leading contract research organization in integrated fragment-based drug discovery, recently announced significant progress made as part of their collaboration to identify therapeutic lead candidates for Gotham’s initial portfolio of epitranscriptomic targets